If you're late to the biotech trade, AMGN still offers a great trading opportunity in the short-term. More
-
-
Sponsored By:
-
Sponsored By:
Biotech
Including this topic: Biotech Movers
Recent Articles
2 Stocks to Buy, 2 to Sell in Big Pharma
Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries. More
Bull’s Eye Report:Isis Pharmaceuticals (ISIS)
Biotechs are blowing up -- and ISIS Pharmaceuticals (ISIS) is showing an attractive buy right now with potential 12% upside. More
Bull’s Eye Report: Acorda Therapeutics (ACOR)
Though lackluster earnings are usually a reason NOT to buy a stock, ACOR gracefully bottomed and based above the 50-day moving average last week and looks to be turning around. More
3 Hot Biotechs to Keep on Your Radar
The key to successfully investing in these biotechs is being able to sort the winners from the losers. Here are three picks that get a thumbs-up. More
Bull’s Eye Report: Amgen (AMGN)
Biotech has been a top performer in 2013, and Amgen (AMGN) is no exception. The recent basing pattern in the stock makes for a great buy point. More
Bull’s Eye Report: Pharmacyclics (PCYC)
Pharmacyclics (PCYC) is our top pick today as an outperformer in the biotech space. More
